Life Science News

Johnson & Johnson (NYSE: JNJ) will participate in the Credit Suisse 31 st Annual Global Healthcare Conference on Thursday, November 10 th , 2022 at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals will represent the Company in a session scheduled at 12:50 p.m. (Eastern Time).

This audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

The audio webcast replay will be available approximately 48 hours after the live webcast.

Press Contact:

Linda Fedow
(732) 524-6071

Investor Contact:

Raychel Kruper
(732) 524-6164

News Provided by Business Wire via QuoteMedia

JNJ

Kaleido Collaborates with Janssen on Metabolic Therapies

Kaleido Biosciences (NADAQ:KLDO) announced a research collaboration with Janssen’s World Without Disease Accelerator, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE:JNJ).

As quoted in the press release:

Keep reading...Show less

XBiotech Sells Human Antibody to Janssen for US$750 Million

XBiotech (NASDAQ:XBIT) announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson’s (NYSE:JNJ) Janssen Biotech.

As quoted in the press release:

Keep reading...Show less
CSE:BOSS

YIELD GROWTH Announces 130 Retail Locations Confirmed to Sell Urban Juve Products

The Yield Growth Corp. (CSE:BOSS, OTCQB:BOSQF, Frankfurt:YG3) is pleased to announce that 130 retail locations across Canada and the US have agreed to sell Urban Juve products with 90 retail locations now live with product. The locations are diverse geographically, and will bring luxury, hemp-powered skincare products to new markets across North America.

Keep reading...Show less

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership

Aduro Biotech (NASDAQ:ADRO) announced the recent initiation of a Phase 1b study of ADU-214 (JNJ-64041757) in combination with nivolumab for the treatment of advanced lung cancer. ADU-214 is an immunotherapy based on Aduro’s live, attenuated double-deleted Listeria (LADD) technology platform in development for the treatment of advanced or metastatic non-small cell lung cancer. Janssen Biotech, Inc. (Janssen), Aduro’s license partner for ADU-214, is conducting the global trial.

As quoted in the press release:

Keep reading...Show less

Minerva Neurosciences to Report First Quarter 2016 Financial Results and Business Updates on May 3, 2016

| Source:Minerva Neurosciences, Inc.



WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the first quarter of 2016 on Tuesday, May 3, 2016.  The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates.
The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 74086869.  A live webcast of the conference call will be available online in the Investors and Media section of the Company’s website at ir.minervaneurosciences.com.  The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 30 days.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases.  Minerva’s proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials for insomnia and major depressive disorder (MDD), respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease.  Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”  For more information, please visit www.minervaneurosciences.com.






Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2023

The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2022. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 45 consecutive years. The dividend is payable on January 13, 2023, to shareholders of record at the close of business on December 21, 2022.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow @Medtronic on Twitter and LinkedIn .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Johnson & Johnson (NYSE: JNJ) will participate in the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9 th , at the Westin St. Francis in San Francisco, CA. Joaquin Duato, Chairman Elect of the Board and Chief Executive Officer will represent the Company in a session scheduled at 12:45 p.m. (Eastern Time).

This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions

Company to achieve 2030 Scope 1 and 2 greenhouse gas emissions reduction target of 30% ahead of schedule; increases ambition to 50% reduction, aligned with 1.5˚C pathway

Thermo Fisher Scientific Inc . (NYSE: TMO), the world leader in serving science, today announced a new 2030 greenhouse gas emissions reduction target to reduce its Scope 1 and 2 emissions from operations by more than 50% from a 2018 baseline. 1 The company is on track to achieve its previous 2030 goal of a 30% reduction, ahead of schedule.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Medtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patients with atrial fibrillation

SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system

Medtronic (NYSE:MDT) today announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial designed to evaluate the safety and effectiveness of the first-of-its kind Sphere-9™ pulsed field (PF) and radiofrequency (RF) ablation, and high density (HD) mapping catheter with the Affera cardiac mapping and navigation platform for the treatment of persistent atrial fibrillation (AF).

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Bausch Health Wins DUOBRII and BRYHALI Patent Infringement Case

Bausch Health Companies Inc. (NYSETSX:BHC) today announced that the US District Court for the District of New Jersey issued a favorable decision regarding DUOBRII® and BRYHALI®, in a suit filed against Padagis Israel Pharmaceuticals LTD and Padagis US LLC. According to the ruling, the District Court found all the asserted patents valid and infringed. The current decision will serve to prevent approval of Padagis BRYHALI® and DUOBRII® generics until patent expiry in 2031 and 2036, respectively

DUOBRII® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, is a prescription medicine used on the skin (topical) to treat adults with plaque psoriasis. BRYHALI® (halobetasol propionate) Lotion, 0.01% is a prescription medicine used on the skin (topical) to treat adults with plaque psoriasis.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider

  • Launching in December for Constipation Awareness Month, Initiatives Include Partnerships with Well-Known Lifestyle and Health Care Practitioner Influencers
  • Campaign Coincides with Salix's Continued Support of Advocacy Groups Building Innovative Patient Education Programs and Advancing Disease State Research in 2023

Salix Pharmaceuticals ("Salix"), the gastroenterology business of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health"), today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December. The initiatives will discuss constipation diseases, including opioid-induced constipation (OIC), irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It is estimated that approximately up to 80% of patients receiving opioid medications for chronic pain experience OIC,1 30 million adults have CIC,2,3 and 3.4 million have IBS-C.2,3

The initiatives launching this month culminate a year in which Salix invested in a multipronged educational campaign that included the publication of digital content reaching more than 240 million consumers with valuable information about the symptoms of OIC, IBS-C, and CIC and treatment options they can discuss with their health care providers.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×